• Belite Bio Chief Medical Officer Hendrik Peter Scholl reported selling 500 American depositary shares on Oct. 1.
• Sales prices ranged from USD 163.625 to USD 170.02 per share.
• Indirect holding via Bioptima Ltd. fell to 14,500 American depositary shares.
• Transactions were executed under a Rule 10b5-1 trading plan adopted on June 25, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Belite Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-414643), on October 05, 2026, and is solely responsible for the information contained therein.